{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:01:16Z","timestamp":1780290076930,"version":"3.54.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Objectives<\/jats:title>\n To evaluate the efficacy and safety of iguratimod as maintenance therapy in patients with stable systemic lupus erythematosus (SLE).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Eligible participants were adults with stable SLE (SLEDAI-2K \u22644 for \u226512 weeks) and on stable standard-of-care medication. Patients treated with iguratimod (iguratimod group) were matched to those not receiving iguratimod (control group) using prospectively frequency matching at a 1:2 ratio. The coprimary end points were the flare rate at week 52 and the time to first flare.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This prospective cohort study consecutively screened 220 patients, of whom 52 meeting the inclusion criteria were enrolled. The final analysis included 16 patients in the iguratimod group and 31 in the control group. In the coprimary analysis, The flare rates at week 52 were 37.5% in the iguratimod group and 29% in the control group. Iguratimod was associated with a non-significant, numerically higher relapse risk versus control (HR = 1.45, 95% CI 0.57 to 3.74), with sensitivity analyses confirming the direction of this trend. No significant between-group differences were observed in the changes of secondary endpoints. Regarding safety, iguratimod was well-tolerated, and no serious adverse events were reported.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This cohort study of 52 stable SLE patients found that the 52-week flare risk did not differ significantly between those exposed to iguratimod and those who were not. However, these null findings should be interpreted with caution and are not evidence of equivalence.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1810291","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:19:15Z","timestamp":1780287555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of iguratimod treatment in stable systemic lupus erythematosus: a preliminary prospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Department of Rheumatology, Zhuhai Branch of The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Zhuhai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Shen","sequence":"additional","affiliation":[{"name":"Neher\u2019s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology","place":["Macau, Macau SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengdong","family":"Shen","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Department of Rheumatology, Zhuhai Branch of The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Zhuhai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Chu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Department of Rheumatology, Zhuhai Branch of The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Zhuhai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxin","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review.","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/annrheumdis-2016-209489","article-title":"Remission in systemic lupus erythematosus: durable remission is rare.","volume":"76","author":"Wilhelm","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e001363","DOI":"10.1136\/lupus-2024-001363","article-title":"Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus.","volume":"12","author":"Kandane-Rathnayake","year":"2025","journal-title":"Lupus Sci Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and Low Disease Activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"103773","DOI":"10.1016\/j.autrev.2025.103773","article-title":"Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force.","volume":"24","author":"Piga","year":"2025","journal-title":"Autoimmun Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus.","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus.","volume":"383","author":"Morand","year":"2023","journal-title":"BMJ."},{"key":"B8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.","volume":"121","author":"L\u00fc","year":"2008","journal-title":"Chin Med J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10165-006-0542-y","article-title":"Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.","volume":"17","author":"Hara","year":"2007","journal-title":"Mod Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.","volume":"24","author":"Hara","year":"2014","journal-title":"Mod Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13075-020-02154-7","article-title":"Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study.","volume":"22","author":"Kang","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1062919","DOI":"10.3389\/fimmu.2023.1062919","article-title":"Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: a preliminary investigational study.","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e108273","DOI":"10.1371\/journal.pone.0108273","article-title":"Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL\/lpr mice.","volume":"9","author":"Yan","year":"2014","journal-title":"PLoS One."},{"key":"B15","doi-asserted-by":"publisher","first-page":"107563","DOI":"10.1016\/j.intimp.2021.107563","article-title":"Iguratimod ameliorates nephritis by modulating the Th17\/Treg paradigm in pristane-induced lupus.","volume":"96","author":"Xia","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus.","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1186\/s13063-021-05475-3","article-title":"Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study).","volume":"22","author":"Yan","year":"2021","journal-title":"Trials."},{"key":"B18","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/ar3202","article-title":"Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.","volume":"12","author":"Djabarouti","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1093\/rheumatology\/keab953","article-title":"Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus.","volume":"61","author":"Miyazaki","year":"2022","journal-title":"Rheumatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force.","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.2147\/JIR.S504995","article-title":"Prediction of flares in systemic lupus erythematosus during post-remission follow-up.","volume":"18","author":"Bai","year":"2025","journal-title":"J Inflamm Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/acr.24464","article-title":"Prevalence, predictors, and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review.","volume":"74","author":"Yang","year":"2022","journal-title":"Arthritis Care Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e000616","DOI":"10.1136\/lupus-2021-000616","article-title":"LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.","volume":"9","author":"Ugarte-Gil","year":"2022","journal-title":"Lupus Sci Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2665-9913(24)00121-8","article-title":"Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.","volume":"6","author":"Golder","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25690","article-title":"American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus.","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/ard-2024-225826","article-title":"Evaluation and prediction of relapse risk in stable systemic lupus erythematosus patients after glucocorticoid withdrawal (PRESS): an open-label, multicentre, non-inferiority, randomised controlled study in China.","volume":"84","author":"Fei","year":"2025","journal-title":"Ann Rheum Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1546306","DOI":"10.3389\/fimmu.2025.1546306","article-title":"Transitioning from lupus low disease activity state to remission in systemic lupus erythematosus: real-world evidence.","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus.","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810291\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:19:16Z","timestamp":1780287556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810291\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1810291"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1810291","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1810291"}}